"20" . "Musil, Franti\u0161ek" . . "L\u00E9\u010Dba dyslipid\u00E9mi\u00ED u diabetik\u016F 2. typu"@cs . "[961C05DB62C8]" . . "0862-8947" . "L\u00E9\u010Dba dyslipid\u00E9mi\u00ED u diabetik\u016F 2. typu" . . "Komplexn\u00ED l\u00E9\u010Dba DM 2. typu vede k prodlou\u017Een\u00ED \u017Eivota, zlep\u0161en\u00ED kvality a prevenci \u010Di odd\u00E1len\u00ED vzniku makrovaskul\u00E1rn\u00EDch a mikrovaskul\u00E1rn\u00EDch komplikac\u00ED. Dosa\u017Een\u00ED t\u011Bchto c\u00EDl\u016F v l\u00E9\u010Db\u011B dyslipid\u00E9mie je u DM 2. typu, kter\u00FD zahrnuje jedince s vysok\u00FDm kardiovaskul\u00E1rn\u00EDm rizikem obt\u00ED\u017En\u00E9, navzdory dietn\u00ED, re\u017Eimov\u00E9 a farmakologick\u00E9 intervenci. I kdy\u017E l\u00E9\u010Dba statiny u diabetik\u016F 2.typu prokazateln\u011B sni\u017Euje kardiovaskul\u00E1rn\u00ED riziko, st\u00E1le z\u016Fst\u00E1v\u00E1 i ve skupin\u011B aktivn\u011B l\u00E9\u010Den\u00FDch pacient\u016F signifikantn\u00ED rezidu\u00E1ln\u00ED riziko. Proto je dal\u0161\u00EDm c\u00EDlem v l\u00E9\u010Db\u011B dyslipid\u00E9mie - vedle dosa\u017Een\u00ED n\u00E1le\u017Eit\u00FDch hodnot LDL - snaha zv\u00FD\u0161it HDL-cholesterol a sn\u00ED\u017Eit triglycerid\u00E9mii pomoc\u00ED dal\u0161\u00EDch hypolipidemik v r\u00E1mci kombinovan\u00E9 hypolipidemick\u00E9 terapie. Mo\u017En\u00E9 kombinace hypolipidemik zahrnuj\u00ED p\u0159edev\u0161\u00EDm fibr\u00E1t + statin, a mezi dal\u0161\u00ED kombinace pat\u0159\u00ED l\u00E9\u010Dba typu fibr\u00E1t + niacin, fibr\u00E1t + ezetimibe, statin + niacin p\u0159\u00EDpadn\u011B + ezetimibe nebo omega-3 mastn\u00E9 kyseliny." . "RIV/00216208:11150/10:10075534!RIV11-MZ0-11150___" . "A complex treatment of diabetes mellitus type 2 is associated with prolongation of the human life, improvement of it quality and prevention of macro- and microvascular complications. To reach such goals in the treatment of dyslipidemia in diabetes mellitus type 2 with high risk cardiovascular patients is very difficult, despite a diet, life style and pharmacological intervention. Despite statin treatment, cardiovascular disease residual risk remains high. After LDL the next lipoprotein goal is to increase HDL. The choice of appropriate combination of hypolipidemic agents and monitoring for possible side effects, tolerance and compliance of patients is necessary, namely because of increased number of drug interactions a side effects of combination therapy. The possible combinations include namely statin + fibrate, and further combination include fibrate + niacin, fibrate + ezetimibe, statin + niacin or + ezetimibe, or omega-3 fatty-acids."@en . "RIV/00216208:11150/10:10075534" . "L\u00E9\u010Dba dyslipid\u00E9mi\u00ED u diabetik\u016F 2. typu"@cs . "Komplexn\u00ED l\u00E9\u010Dba DM 2. typu vede k prodlou\u017Een\u00ED \u017Eivota, zlep\u0161en\u00ED kvality a prevenci \u010Di odd\u00E1len\u00ED vzniku makrovaskul\u00E1rn\u00EDch a mikrovaskul\u00E1rn\u00EDch komplikac\u00ED. Dosa\u017Een\u00ED t\u011Bchto c\u00EDl\u016F v l\u00E9\u010Db\u011B dyslipid\u00E9mie je u DM 2. typu, kter\u00FD zahrnuje jedince s vysok\u00FDm kardiovaskul\u00E1rn\u00EDm rizikem obt\u00ED\u017En\u00E9, navzdory dietn\u00ED, re\u017Eimov\u00E9 a farmakologick\u00E9 intervenci. I kdy\u017E l\u00E9\u010Dba statiny u diabetik\u016F 2.typu prokazateln\u011B sni\u017Euje kardiovaskul\u00E1rn\u00ED riziko, st\u00E1le z\u016Fst\u00E1v\u00E1 i ve skupin\u011B aktivn\u011B l\u00E9\u010Den\u00FDch pacient\u016F signifikantn\u00ED rezidu\u00E1ln\u00ED riziko. Proto je dal\u0161\u00EDm c\u00EDlem v l\u00E9\u010Db\u011B dyslipid\u00E9mie - vedle dosa\u017Een\u00ED n\u00E1le\u017Eit\u00FDch hodnot LDL - snaha zv\u00FD\u0161it HDL-cholesterol a sn\u00ED\u017Eit triglycerid\u00E9mii pomoc\u00ED dal\u0161\u00EDch hypolipidemik v r\u00E1mci kombinovan\u00E9 hypolipidemick\u00E9 terapie. Mo\u017En\u00E9 kombinace hypolipidemik zahrnuj\u00ED p\u0159edev\u0161\u00EDm fibr\u00E1t + statin, a mezi dal\u0161\u00ED kombinace pat\u0159\u00ED l\u00E9\u010Dba typu fibr\u00E1t + niacin, fibr\u00E1t + ezetimibe, statin + niacin p\u0159\u00EDpadn\u011B + ezetimibe nebo omega-3 mastn\u00E9 kyseliny."@cs . "Treatment of dyslipidemia in patients with type 2 diabetes mellitus"@en . "L\u00E9\u010Dba dyslipid\u00E9mi\u00ED u diabetik\u016F 2. typu" . "2"^^ . "Treatment of dyslipidemia in patients with type 2 diabetes mellitus"@en . . . "268116" . "5" . . . . "3"^^ . . . . . "V\u00ED\u0161ek, Jakub" . . . "11"^^ . "atherosclerosis; cardiovascular risk; hypolipidemic treatment; dyslipidemia; Type 2 diabetes mellitus"@en . "P(NS9743), Z(MSM0021620820)" . "CZ - \u010Cesk\u00E1 republika" . "Bl\u00E1ha, Vladim\u00EDr" . . . "11150" . . . "Remedia" . . .